Tel-Aviv, Israel, September 12, 2016 / B3C newswire / -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary …
The Phase Ib/II clinical study is intended to evaluate the safety and efficacy of YELIVA™ (ABC294640) in patients with refractory or relapsed multiple myeloma and is supported by a $2 million grant from the National Cancer Institute (NCI), awarded to …
Patent and market authorization for human hyperacute serum product Krems an der Donau, Austria, September 07, 2016 / B3C newswire / -- OrthoSera GmbH, an orthobiologics company developing serum-based solutions for musculoskeletal indications announces that …
Heidelberg, Germany, September 06, 2016 / B3C newswire / -- BioMed X Innovation Center announced today the official start of a new research group established through joint crowdsourcing efforts with Johnson & Johnson Consumer Inc. as a continuum of …
Tokyo, Japan, September 06, 2016 / B3C newswire / -- AGC Asahi Glass (AGC), a world-leading manufacturer of glass, chemicals and high-tech materials, announces that it has acquired all of the shares of Biomeva GmbH (Biomeva) from Biomeva Holding GmbH. …
Basel, Switzerland and Aprilia, Italy, 05 September, 2016 / B3C newswire / -- IBI-Lorenzini has entered into a partnership with the Swiss contract development and manufacturing organisation, Celonic, to establish high performance cell lines for R&D. …
Unique product and service portfolio extensively covers all steps from cell line development to commercial manufacturing processes Goettingen, Germany / Aubagne, France, September 01, 2016 / B3C newswire / -- Sartorius Stedim Biotech (SSB), an …
Melbourne, Australia, September 01, 2016 / B3C newswire / -- Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, today announced Mr Thomas Lynch as Adherium’s new Chairman, …
RedHill has received from the European Patent Office a Notice of Intention to Grant a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted A Phase IIa proof-of-concept study evaluating RHB-104 in patients …
AYOXXA Reader AR01 is ready for the market Cologne, Germany, August 22, 2016 / B3C newswire / -- AYOXXA Biosystems GmbH, an international biotechnology company, and Märzhäuser Wetzlar GmbH & Co KG, a leading precision equipment manufacturer, joined …
Tel-Aviv, Israel, August 11, 2016 / B3C newswire / -- RedHill Biopharma Ltd. (NASDAQ: RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, …
Kraków, Poland, August 9, 2016 / B3C newswire / -- Selvita Inc., the US subsidiary of Selvita S.A., headquartered in Cambridge, MA, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF). The project will …
Fully automated data transfer improves diabetes management Potsdam, Germany, August 4, 2016 / B3C newswire / -- Emperra GmbH based in Germany is launching the world’s first Bluetooth® insulin pen on the market and therefore expanding its ESYSTA® product …
Garching, Germany, August 4, 2016 / B3C newswire / -- ITM Isotopen Technologien München AG, a specialized radiopharmaceutical company, today announced that the European Medicines Agency (EMA) has granted Marketing Authorization for EndolucinBeta® of ITM´ …
The Phase IIa proof-of-concept study evaluates the safety and potential efficacy of fixed oral dose RHB-104 as an add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (RRMS) Analysis of the study is ongoing, with top-line final …
Leuven, Belgium, August 1, 2016 / B3C newswire / -- Trod Medical NV, the medical device company with FDA-cleared and CE Marked products for focal ablation, announces the issuance of a new patent allowance by the United States Patent and Trademark Office ( …
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, UK, July 28, 2016 / B3C newswire / -- Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company …
Langenfeld, Germany /Melbourne, Australia July 26, 2016 / B3C newswire / -- ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis C virus (HCV). An HCV vaccine …
Munich, Germany, July 25, 2016 / B3C newswire / -- Morphochem, a clinical-stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated Morphochem’s intravenous (IV) antibacterial product candidate MCB3837 as …
RedHill has received a Notice of Allowance for an additional U.S. patent covering RHB-105, expected to be valid until 2034 once granted The planned confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, if successful, is …
